1. Pink Sheet
  2. >>Geography
  3. >>Europe

Mirati To Challenge EMA’s Rejection Of US-Approved Krazati

Drug Was Granted Accelerated Approval By US FDA In December 2022

 
• By Neena Brizmohun

Mirati Therapeutics said it disagreed with the European Medicines Agency’s decision that its lung cancer drug did not meet its conditional marketing authorization criteria.

Concept of EMA European Medicines Agency. Drugs evaluation and quality control.
The EMA says Krazati should not be approved in the EU • Source: Shutterstock

Mirati Therapeutics is to appeal against the European Medicines Agency’s recommendation that pan-EU marketing approval should be refused for Krazati (adagrasib), the company’s US-approved treatment for KRASG12C -mutated advanced non-small cell lung cancer (NSCLC).

Mirati was seeking a conditional marketing authorization for the drug, but the EMA said today that the medicine did not...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

Engage With HTA Body NICE Before Submitting MAA, UK Govt Tells Companies

 
• By Neena Brizmohun

The government has explained how to navigate the UK’s regulatory and market access funding mechanisms.

EU Pharma Reform: Council Wants Strengthened Member State Powers On Drug Supply

 
• By Eliza Slawther

The Council of the EU’s vision for the pharma reform package includes a stronger role for member states regarding the supply of medicines and the prevention of indication-stacking for orphan drugs.

EU Sees Unified Pathway For Drug/IVD Studies As Key To Future Research Investment

 
• By Vibha Sharma

As the EU tests the feasibility of a radical “all-in-one” procedure for combined drug and IVD studies, sponsors are being urged to approach this novel framework with flexibility and openness.

EU CHMP Opinions And MAA Updates

 
• By Neena Brizmohun

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

More from Geography

Engage With HTA Body NICE Before Submitting MAA, UK Govt Tells Companies

 
• By Neena Brizmohun

The government has explained how to navigate the UK’s regulatory and market access funding mechanisms.

EU Pharma Reform: Council Wants Strengthened Member State Powers On Drug Supply

 
• By Eliza Slawther

The Council of the EU’s vision for the pharma reform package includes a stronger role for member states regarding the supply of medicines and the prevention of indication-stacking for orphan drugs.

Quotable: Top Experts On Policy Hot Topics

 
• By Anabel Costa-Ferreira

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.